VD's Model Portfolio & Discussion Thread Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: JMarcus who wrote (7454)	1/11/2000 7:47:00 PM
From: scaram(o)uche	Read Replies (2) of 9719

Marc: Foreign proteins are immunogenic. This is a rehash of a very old story, IMO. Never works. >> don't you think the following new platform technology sounds exciting? << No. Doesn't sound new, either. Therefore, based on the initial clinical success of both monoclonal antibodies and other fusion toxins, several of which have been approved and effectively launched Well, yes.... humanized MAbs have been launched, and fusion toxins for topical use have been launched. However, to my knowledge no toxin immunoconjugates or fusion toxins have been approved for systemic use. Aside...... ABSC 41 +4 3/4 41 37 1/16 13090 +13.1% Sheesh, again? Sigh. Another one escapes my portfolio. Nice, V1!

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next